A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Official Title

A Multicentre, Open-Label, Phase I Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Summary:

This is a Phase I, multicentre, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), RO7082859, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following the pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-to-human study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or optimal biological dose (OBD). The expansion cohorts (Part III) will be initiated when the tentative MTD/OBD is defined, to further evaluate the safety, PK and therapeutic activity of RO7082859.

Trial Description

Primary Outcome:

  • Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs)
  • Part I, II and III: Percentage of Participants With Adverse Events (AEs)
  • Part II: MTD or OBD of RO7082859
  • Part II: Recommended Phase II Dose (RP2D) of RO7082859
  • Part III: Complete Response (CR) Rate as Assessed by Independent Review Committee (IRC) According to Standard Non-Hodgkin's Lymphoma (NHL) Response Criteria (Lugano Classification)
  • Part I, II and III: Area Under the Serum Concentration Versus Time Curve (AUC) of RO7082859
  • Part I, II and III: Maximum Serum Concentration (Cmax) of RO7082859
  • Part I, II and III: Minimum Serum Concentration (Cmin) of RO7082859
  • Part I, II and III: Clearance (CL) of RO7082859
  • Part I, II and III: Volume of Distribution at Steady-State (Vss) of RO7082859
  • Part I, II and III: Half-Life (t1/2) of RO7082859
Secondary Outcome:
  • Part I, II and III: Cmax of Obinutuzumab
  • Part I, II and III: Cmin of Obinutuzumab
  • Part I, II and III: Anti-Drug Antibodies (ADA) to RO7082859
  • Parts I and II: Percentage of Participants With Overall Response (Partial Response [PR] or Complete Response [CR]) as Determined by the Lugano Classification
  • Part I, II and III: Percentage of Participants With PR or CR (Overall Response Rate) as Determined by the Lugano Classifications
  • Part I, II and III: Duration of Response (DOR) as Determined by the Lugano Classification
  • Part I, II and III: Duration of Complete Response (DOCR) as Determined by the Lugano Classification
  • Part I, II and III: Progression-Free Survival (PFS) as Determined by the Lugano Classification
  • Overall Survival (OS)
  • Time to First Overall Response (TFOR)
  • Time to First Complete Response (TFCR)
  • Health Related Quality of Life (HRQoL) as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
  • HRQoL as Assessed by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Scale

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society